Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2023 Apr 13

PMID 37053275

Authors

Constance C F M J Baaten

Sonja Vondenhoff

Heidi Noels

Affiliations

Soon will be listed here.

Abstract

The endothelium is considered to be the gatekeeper of the vessel wall, maintaining and regulating vascular integrity. In patients with chronic kidney disease, protective endothelial cell functions are impaired due to the proinflammatory, prothrombotic and uremic environment caused by the decline in kidney function, adding to the increase in cardiovascular complications in this vulnerable patient population. In this review, we discuss endothelial cell functioning in healthy conditions and the contribution of endothelial cell dysfunction to cardiovascular disease. Further, we summarize the phenotypic changes of the endothelium in chronic kidney disease patients and the relation of endothelial cell dysfunction to cardiovascular risk in chronic kidney disease. We also review the mechanisms that underlie endothelial changes in chronic kidney disease and consider potential pharmacological interventions that can ameliorate endothelial health.

Citing Articles

Cardiovascular risk prediction in hemodialysis patients using the triglyceride-glucose index: a multicenter prospective cohort study.

Lee Y, Kang S, Kim D, Kim J, Jeong K, Kim Y Clin Kidney J. 2025; 18(3):sfaf016.

PMID: 40052161 PMC: 11883225. DOI: 10.1093/ckj/sfaf016.

Clinical outcomes after complex and high-risk percutaneous coronary intervention according to baseline chronic kidney disease.

Di Muro F, Sartori S, Vogel B, Feng Y, Gitto M, Oliva A Clin Res Cardiol. 2025; .

PMID: 39998662 DOI: 10.1007/s00392-025-02618-3.

Progress in the application of novel inflammatory indicators in chronic kidney disease.

Gao W, Wang X, Zou Y, Wang S, Dou J, Qian S Front Med (Lausanne). 2025; 12:1500166.

PMID: 39950124 PMC: 11821595. DOI: 10.3389/fmed.2025.1500166.

Exploring the Relationship Between Ejection Fraction, Arterial Stiffness, NT-proBNP, and Hospitalization Risk in Heart Failure Patients.

Osser G, Osser B, Toth C, Miuta C, Marconi G, Bondar L Diagnostics (Basel). 2025; 14(24.

PMID: 39767246 PMC: 11675150. DOI: 10.3390/diagnostics14242885.

Stick to the Script: How Endomucin Keeps the Glycocalyx in Line.

McMillan R, Rodriguez B, Kirabo A Circ Res. 2025; 136(1):75-77.

PMID: 39745991 PMC: 11698490. DOI: 10.1161/CIRCRESAHA.124.325805.

References

Ehling J, Babickova J, Gremse F, Klinkhammer B, Baetke S, Knuechel R . Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. J Am Soc Nephrol. 2015; 27(2):520-32. PMC: 4724942. DOI: 10.1681/ASN.2015020204. View

Kaur J, Young B, Fadel P . Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. Int J Mol Sci. 2017; 18(8). PMC: 5578072. DOI: 10.3390/ijms18081682. View

Salmon A, Ferguson J, Burford J, Gevorgyan H, Nakano D, Harper S . Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012; 23(8):1339-50. PMC: 3402289. DOI: 10.1681/ASN.2012010017. View

Folco E, Mawson T, Vromman A, Bernardes-Souza B, Franck G, Persson O . Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1α and Cathepsin G. Arterioscler Thromb Vasc Biol. 2018; 38(8):1901-1912. PMC: 6202190. DOI: 10.1161/ATVBAHA.118.311150. View

Zhang H, Xiang S, Dai Z, Fan Y . Asymmetric dimethylarginine level as biomarkers of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis. Biomarkers. 2021; 26(7):579-585. DOI: 10.1080/1354750X.2021.1954694. View

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

Thethi T, Bajwa M, Ghanim H, Jo C, Weir M, Goldfine A . Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. J Diabetes Complications. 2015; 29(3):433-7. PMC: 4392813. DOI: 10.1016/j.jdiacomp.2015.01.004. View

Zieman S, Melenovsky V, Kass D . Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25(5):932-43. DOI: 10.1161/01.ATV.0000160548.78317.29. View

Guerin A, London G, Marchais S, Metivier F . Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15(7):1014-21. DOI: 10.1093/ndt/15.7.1014. View

10.

de Lomana A, Vilhjalmsson A, McGarrity S, Sigurdardottir R, Anuforo O, Viktorsdottir A . Metabolic Response in Endothelial Cells to Catecholamine Stimulation Associated with Increased Vascular Permeability. Int J Mol Sci. 2022; 23(6). PMC: 8950318. DOI: 10.3390/ijms23063162. View

11.

Chen X, Dodd G, Thomas S, Zhang X, Wasserman M, Rovin B . Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2005; 290(5):H1862-70. DOI: 10.1152/ajpheart.00651.2005. View

12.

Moranne O, Froissart M, Rossert J, Gauci C, Boffa J, Haymann J . Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2008; 20(1):164-71. PMC: 2615728. DOI: 10.1681/ASN.2008020159. View

13.

Six I, Gross P, Remond M, Chillon J, Poirot S, Drueke T . Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120. Atherosclerosis. 2015; 243(1):248-56. DOI: 10.1016/j.atherosclerosis.2015.09.019. View

14.

Jacobson S, Egberg N, Hylander B, Lundahl J . Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol. 2002; 22(1):42-7. DOI: 10.1159/000046673. View

15.

Zhang L, Yao J, Yao Y, Bostrom K . Contributions of the Endothelium to Vascular Calcification. Front Cell Dev Biol. 2021; 9:620882. PMC: 8165270. DOI: 10.3389/fcell.2021.620882. View

16.

Farquharson C, Struthers A . Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101(6):594-7. DOI: 10.1161/01.cir.101.6.594. View

17.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

18.

. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365):1788-1801. PMC: 7613836. DOI: 10.1016/S0140-6736(22)02074-8. View

19.

Schnabel R, Schulz A, Wild P, Sinning C, Wilde S, Eleftheriadis M . Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging. 2011; 4(4):371-80. DOI: 10.1161/CIRCIMAGING.110.961557. View

20.

Soppert J, Lehrke M, Marx N, Jankowski J, Noels H . Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020; 159:4-33. DOI: 10.1016/j.addr.2020.07.019. View